Cambridge IPOs
22 companies in Cambridge tracking toward an IPO in 2026.
24M Technologies
24M Technologies develops advanced lithium-ion battery manufacturing technology and designs, focusing on reducing costs and improving performance for electric vehicles and energy storage. The company's innovative battery technology has attracted attention from investors interested in the growing electric vehicle and energy storage markets.
Akamai Technologies
Akamai is a leading content delivery network (CDN) and cloud services company that helps organizations deliver secure, high-performance digital experiences. The company's platform spans security, web performance, and edge computing services for enterprises worldwide.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing technology. The company's platform enables single letter changes in DNA without double-strand breaks, potentially offering safer gene editing approaches. Investors are interested in its differentiated technology and pipeline addressing liver diseases, blood disorders, and ocular conditions.
Cambridge Mobile Telematics
Cambridge Mobile Telematics (CMT) provides telematics and behavioral analytics solutions for auto insurance companies, enabling usage-based insurance programs and driver behavior scoring. The company's platform uses smartphone sensors and IoT devices to assess driving patterns and risk. Investors are interested in the growing insurtech market and data-driven insurance solutions.
Cellarity
Cellarity is a biotechnology company that uses artificial intelligence and machine learning to analyze cellular behavior and develop new drugs. The company's platform examines how cells function as dynamic systems to identify novel therapeutic targets and accelerate drug discovery.
Commonwealth Fusion Systems
Commonwealth Fusion Systems is developing commercial fusion energy technology using high-temperature superconducting magnets to create compact fusion reactors. The MIT spinoff aims to demonstrate net energy gain from fusion and eventually commercialize fusion power plants. Investors are attracted to the company's potential to solve global energy challenges through clean, abundant fusion energy, though the technology remains in development stages.
ConcertAI
ConcertAI is a healthcare technology company that uses artificial intelligence and real-world data to accelerate drug development and improve patient outcomes. The company provides AI-powered solutions to pharmaceutical companies, health systems, and life sciences organizations for clinical research and precision medicine.
Devo
Devo is a security operations and observability platform that provides real-time data analytics for cybersecurity and IT operations teams. The company's cloud-native platform helps organizations detect threats, investigate incidents, and maintain visibility across their IT infrastructure and security environments.
Editas Medicine
Editas Medicine is a leading genome editing company focused on developing CRISPR-based medicines for serious diseases. The company's pipeline includes treatments for inherited retinal dystrophies, sickle cell disease, and various cancers. Investors value its pioneering position in the CRISPR therapeutics space and partnerships with major pharmaceutical companies.
EQRx
EQRx was a biotechnology company focused on developing innovative medicines at radically lower prices through a new approach to drug pricing and development. The company aimed to make high-quality medicines accessible globally by reimagining the traditional pharmaceutical business model.
Generate Biomedicines
Generate Biomedicines is developing a machine learning platform to create novel proteins and medicines on demand. The company aims to revolutionize drug discovery by using AI to generate new protein-based therapeutics that could address previously undruggable targets.
Inari
Inari is an agricultural technology company that develops seed products using predictive design and advanced breeding techniques to help farmers improve crop yields. The company combines computational biology with traditional breeding to create seeds that can better withstand climate challenges and increase agricultural productivity.
Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company developing CRISPR/Cas9-based therapeutics for genetic diseases. The company focuses on both in vivo and ex vivo approaches to treat conditions like transthyretin amyloidosis and primary hyperoxaluria. Investors are attracted to its clinical progress and potential for first-in-class treatments.
Moderna
Moderna is a biotechnology company that develops messenger RNA therapeutics and vaccines to create new medicines for infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. The company gained global prominence for developing one of the first COVID-19 vaccines.
Overjet
Overjet uses artificial intelligence to analyze dental X-rays and help dentists detect issues like cavities and bone loss more accurately and efficiently. The company's AI platform assists with treatment planning and insurance claim processing in dental practices. Investors see potential in Overjet's ability to improve dental care outcomes while addressing the large healthcare AI market opportunity.
Prime Medicine
Prime Medicine is a biotechnology company developing next-generation gene editing therapies using prime editing technology. The company's platform can make precise insertions, deletions, and replacements in DNA with minimal off-target effects. Investors are attracted to its potentially superior precision compared to traditional CRISPR and its broad therapeutic applications.
Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental technologies to develop targeted therapies. The company's protein motion platform and focus on oncology have positioned it as an innovative player in the precision medicine and cancer treatment space.
Sense
Sense is a home energy monitoring company that develops smart home devices and software to help consumers understand and manage their electricity usage. The company's products use machine learning to identify individual appliances and provide insights on energy consumption patterns.
Solo.io
Solo.io provides application networking and security solutions for modern cloud-native environments, including service mesh and API gateway technologies. The company serves enterprises looking to manage microservices architectures and secure their distributed applications. Investors are interested in Solo.io's position in the growing cloud infrastructure market.
Suno
Suno is an AI-powered music generation platform that allows users to create original songs using artificial intelligence. The company's technology can generate vocals, lyrics, and instrumentals based on text prompts or style preferences. Investors are drawn to its potential in the rapidly growing AI content creation market.
Tessera Therapeutics
Tessera Therapeutics is developing Gene Writing technology, a new approach to genetic medicine that can write therapeutic messages into the genome. The company's platform aims to make precise, targeted genetic modifications to treat serious diseases that current gene therapy approaches cannot address.
Verve Therapeutics
Verve Therapeutics is a genetic medicines company focused on developing single-course gene editing treatments for cardiovascular disease. The company's approach to using base editing technology to permanently lower cholesterol and reduce heart disease risk has generated significant interest from investors in the gene editing space.
Track Cambridge IPOs
Get daily alerts when companies in Cambridge file S-1s or announce IPO dates.
Get IPO Alerts